161 related articles for article (PubMed ID: 21324459)
1. Abnormal plasma fibrin clot characteristics are associated with worse clinical outcome in patients with peripheral arterial disease and thromboangiitis obliterans.
Undas A; Nowakowski T; Cieśla-Dul M; Sadowski J
Atherosclerosis; 2011 Apr; 215(2):481-6. PubMed ID: 21324459
[TBL] [Abstract][Full Text] [Related]
2. Unfavorably altered fibrin clot properties in patients with active rheumatoid arthritis.
Kwasny-Krochin B; Gluszko P; Undas A
Thromb Res; 2010 Jul; 126(1):e11-6. PubMed ID: 20471669
[TBL] [Abstract][Full Text] [Related]
3. Altered fibrin clot properties in patients with premature peripheral artery disease.
Okraska-Bylica A; Wilkosz T; Słowik L; Bazanek M; Konieczyńska M; Undas A
Pol Arch Med Wewn; 2012; 122(12):608-15. PubMed ID: 23235487
[TBL] [Abstract][Full Text] [Related]
4. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis.
Konieczynska M; Fil K; Bazanek M; Undas A
Thromb Haemost; 2014 Apr; 111(4):685-93. PubMed ID: 24306139
[TBL] [Abstract][Full Text] [Related]
5. Altered plasma fibrin clot properties in patients with digestive tract cancers: links with the increased thrombin generation.
Gronostaj K; Richter P; Nowak W; Undas A
Thromb Res; 2013 Mar; 131(3):262-7. PubMed ID: 23273404
[TBL] [Abstract][Full Text] [Related]
6. Altered fibrin clot properties in patients on long-term haemodialysis: relation to cardiovascular mortality.
Undas A; Kolarz M; Kopeć G; Tracz W
Nephrol Dial Transplant; 2008 Jun; 23(6):2010-5. PubMed ID: 18156458
[TBL] [Abstract][Full Text] [Related]
7. Thyroid dysfunction and fibrin network structure: a mechanism for increased thrombotic risk in hyperthyroid individuals.
Hooper JM; Stuijver DJ; Orme SM; van Zaane B; Hess K; Gerdes VE; Phoenix F; Rice P; Smith KA; Alzahrani SH; Standeven KF; Ajjan RA
J Clin Endocrinol Metab; 2012 May; 97(5):1463-73. PubMed ID: 22378816
[TBL] [Abstract][Full Text] [Related]
8. Reduced plasma fibrin clot permeability and susceptibility to lysis in patients with inflammatory bowel disease: a novel prothrombotic mechanism.
Owczarek D; Cibor D; Sałapa K; Głowacki MK; Mach T; Undas A
Inflamm Bowel Dis; 2013 Nov; 19(12):2616-24. PubMed ID: 24108112
[TBL] [Abstract][Full Text] [Related]
9. Altered plasma fibrin clot properties are associated with in-stent thrombosis.
Undas A; Zalewski J; Krochin M; Siudak Z; Sadowski M; Pregowski J; Dudek D; Janion M; Witkowski A; Zmudka K
Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):276-82. PubMed ID: 19910643
[TBL] [Abstract][Full Text] [Related]
10. Fibrin clot properties are altered in patients with chronic obstructive pulmonary disease. Beneficial effects of simvastatin treatment.
Undas A; Kaczmarek P; Sladek K; Stepien E; Skucha W; Rzeszutko M; Gorkiewicz-Kot I; Tracz W
Thromb Haemost; 2009 Dec; 102(6):1176-82. PubMed ID: 19967149
[TBL] [Abstract][Full Text] [Related]
11. Assessment of plasma prothrombotic factors in patients with Buerger's disease.
Hus I; Sokolowska B; Walter-Croneck A; Chrapko M; Nowaczynska A; Dmoszynska A
Blood Coagul Fibrinolysis; 2013 Mar; 24(2):133-9. PubMed ID: 23358197
[TBL] [Abstract][Full Text] [Related]
12. Plasma fibrin clot properties in atopic dermatitis: links between thrombosis and atopy.
Nastałek M; Wojas-Pelc A; Undas A
J Thromb Thrombolysis; 2010 Aug; 30(2):121-6. PubMed ID: 20419337
[TBL] [Abstract][Full Text] [Related]
13. Fibrin clot properties in women heterozygous for factor V Leiden mutation: effects of oral contraceptives.
Krzek M; Ciesla-Dul M; Zabczyk M; Undas A
Thromb Res; 2012 Oct; 130(4):e216-21. PubMed ID: 22940058
[TBL] [Abstract][Full Text] [Related]
14. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress.
Undas A; Szułdrzynski K; Stepien E; Zalewski J; Godlewski J; Tracz W; Pasowicz M; Zmudka K
Atherosclerosis; 2008 Feb; 196(2):551-7. PubMed ID: 17640649
[TBL] [Abstract][Full Text] [Related]
15. Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban.
Varin R; Mirshahi S; Mirshahi P; Klein C; Jamshedov J; Chidiac J; Perzborn E; Mirshahi M; Soria C; Soria J
Thromb Res; 2013 Mar; 131(3):e100-9. PubMed ID: 23313382
[TBL] [Abstract][Full Text] [Related]
16. Fibrin clot properties in acute ischemic stroke: relation to neurological deficit.
Undas A; Slowik A; Wolkow P; Szczudlik A; Tracz W
Thromb Res; 2010 Apr; 125(4):357-61. PubMed ID: 19942259
[TBL] [Abstract][Full Text] [Related]
17. Altered fibrin clot properties are associated with residual vein obstruction: effects of lipoprotein(a) and apolipoprotein(a) isoform.
Undas A; Cieśla-Dul M; Drążkiewicz T; Sadowski J
Thromb Res; 2012 Sep; 130(3):e184-7. PubMed ID: 22762941
[TBL] [Abstract][Full Text] [Related]
18. Altered fibrin clot structure/function in patients with cryptogenic ischemic stroke.
Undas A; Podolec P; Zawilska K; Pieculewicz M; Jedliński I; Stepień E; Konarska-Kuszewska E; Weglarz P; Duszyńska M; Hanschke E; Przewlocki T; Tracz W
Stroke; 2009 Apr; 40(4):1499-501. PubMed ID: 19246700
[TBL] [Abstract][Full Text] [Related]
19. Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subjects.
Undas A; Brozek J; Jankowski M; Siudak Z; Szczeklik A; Jakubowski H
Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1397-404. PubMed ID: 16574890
[TBL] [Abstract][Full Text] [Related]
20. Fibrin clot properties in acute stroke: what differs cerebral hemorrhage from cerebral ischemia?
Pera J; Undas A; Topor-Madry R; Jagiella J; Klimkowicz-Mrowiec A; Slowik A
Stroke; 2012 May; 43(5):1412-4. PubMed ID: 22343641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
